Arvinas reports Q3 2026 results, dosing starts in new HPK1 trialNov 3Quarterly updateARV-6723Arvinas Inc.
Intensity moves to resume INVINCIBLE-3 sites, restarts TNBC treatment, reports $9.5M cashAug 11Quarterly updateIntensity Therapeutics, Inc.